Leuven, October 5, 2015 - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that the Company will be presenting three scientific posters at the upcoming European Association for Vision and Eye Research (EVER) conference, October 7-10th in Nice, France.

• Dr. Tine Van Bergen of ThromboGenics will present a poster entitled: Complementary effects of PIGF inhibition and MMC in the improvement of surgical outcome after glaucoma filtration surgery. The data indicate that placental growth factor (PlGF) neutralization in combination with mitomycin-C (MMC) have complementary effects in the improvement of surgical outcome by reducing the fibrosis in the bleb.

• Ir. Isabelle Etienne of ThromboGenics will present a poster entitled: Posterior Vitreous Detachment: more a case of the fibronectin interface than the inner limiting membrane? The outcome of the study indicates that only minimal quantitative changes are observed for the presence of collagen, laminin and fibronectin in the inner limiting membrane (ILM) and the posterior vitreous interface after the induction of posterior vitreous detachment (PVD) by an ocriplasmin analogue in animal models.

• Dr. Koen Willekens of UZ, Ophthalmology, Leuven will present a poster entitled: Imaging of intravitreal injected fluid dispersion. The poster covers a study evaluating optimized minimally invasive imaging methods for studying drug dispersion within the vitreous body. The findings of this study are important as the activity of an intravitreal drug is linked to its dispersion within the vitreous body. Studies were performed in collaboration with the department of Radiology, UZ Leuven and ThromboGenics.

For more information on the above mentioned subjects, please go the research page of the ThromboGenics website.

Dr. Patrik De Haes, ThromboGenics' CEO, said: 'ThromboGenics is committed to high-quality fundamental research in the field of ophthalmology as demonstrated by these findings which will be presented at the upcoming EVER conference. It is this type of research that informs our continuing internal development of a number of potentially next-generation ophthalmology products.'

distributed by